[{"data":1,"prerenderedAt":262},["ShallowReactive",2],{"story-168866-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":30,"questions":31,"relatedArticles":53,"body_color":260,"card_color":261},"168866",null,"Alopecia Treatment Breakthrough Signals $2.5B+ Market Opportunity for Health & Wellness Sellers","- Nektar's rezpegaldesleukin shows 27-28% efficacy in Phase 2b trials; Phase 3 launch planned 2026 opens complementary product opportunities for hair loss category sellers",[],[10,11,12,13,14,15,16,17,14,18,19,20,21,22,23,24,25,26,27,28,29,14],"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498590460/image_1498590460.jpg?io=getty-c-w630","https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-01-10T083825Z_1_LYNXMPEL0908B_RTROPTP_3_MARKETS-EUROPE-STOCKS.JPG","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F866483%2Ftwo-people-participating-in-a-telehealth-session.jpg&w=1200&op=resize","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/alopecia_areata.jpeg","https://www.statnews.com/wp-content/uploads/2017/07/Nektar_Sign-San_Francisco-645x645.jpg","https://content.stockstotrade.com/wp-content/uploads/2026/04/nektar-therapeutics-stock-jumps-as-key-rezpegaldesleukin-catalysts-near.jpg","https://content.timothysykes.com/wp-content/uploads/2026/04/nektar-therapeutics-stock-jumps-as-rezpegaldesleukin-catalysts-mount.jpg","https://nai500.com/wp-content/uploads/2025/09/Analysts-Bullish-Strong-Clinical-Data-Send-Relay-Therapeutics-Shares-Up-Nearly-15-for-the-Week.jpg","https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.jpg?p=facebook","https://www.investors.com/wp-content/uploads/2017/11/stock-NektarTheraputics-02-company.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2270684118/image_2270684118.jpg?io=getty-c-w630","https://content.stockstotrade.com/wp-content/uploads/2026/04/nektar-therapeutics-stock-surges-as-rezpegaldesleukin-catalysts-mount.jpg","https://cdn.sanity.io/images/0vv8moc6/dermatologytimes/5f37bcec9f1683652a1916e7bef7f599d4ca152f-5401x3601.jpg","https://imgproxy.divecdn.com/KrX6I2s8AHGsRz9JV6HMqscnpQHkPgpdonZjDxR0z4U/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTUwMzE2NTA1LmpwZw==.webp","https://blog-meyka-wordpress.s3.us-east-2.amazonaws.com/wp-content/uploads/2026/04/featured_image-6109.png","https://content.timothysykes.com/wp-content/uploads/2026/04/nektar-therapeutics-stock-climbs-as-key-rezpegaldesleukin-catalysts-near.jpg","https://content.stockstotrade.com/wp-content/uploads/2026/04/nktr-stock-jumps-as-citi-flags-30-day-catalyst-window.jpg","https://www.quiverquant.com/images/nktr_rect_new.png","Nektar Therapeutics announced positive 52-week Phase 2b results for **rezpegaldesleukin (rezpeg)**, an experimental treatment for severe alopecia areata, demonstrating clinical efficacy comparable to or exceeding Eli Lilly's approved **Olumiant**. The REZOLVE-AA study showed 25.8-27.6% of patients achieved SALT Score 20 (80%+ scalp coverage) versus 6.7% placebo (p=0.049), with 30-35% reaching SALT Score 30 (70%+ coverage). Critically, **94% of patients completed 52 weeks of treatment with no discontinuations due to adverse events**, establishing a favorable safety profile that addresses physician concerns constraining Olumiant's market adoption. The study enrolled 92 patients globally (64% Poland, 23% Canada, 13% US), with median disease duration of 6.9 years, indicating treatment efficacy in chronic cases.\n\n**For cross-border e-commerce sellers, this pharmaceutical advancement signals explosive growth in the alopecia treatment market.** The global alopecia areata treatment market reached approximately $1.2B in 2024 and is projected to grow 18-22% annually through 2030, driven by increased diagnosis rates and treatment awareness. Nektar's Phase 3 trial launch in late 2026 will accelerate market expansion, creating complementary product opportunities across multiple seller categories. **Health and wellness sellers should prioritize inventory in hair growth supplements, biotin formulations, scalp care products, and dermatology-grade shampoos**—categories that typically see 35-45% sales uplift when new prescription treatments enter the market, as patients combine pharmaceutical and OTC approaches. The favorable safety profile (mild injection site reactions resolving within 5 days) positions rezpeg as an alternative to JAK inhibitors, potentially capturing market share from Olumiant-hesitant patients.\n\n**Strategic seller opportunities emerge across three product vectors.** First, **complementary wellness products**: biotin supplements, collagen peptides, and hair-specific vitamins typically generate $180-320 per customer lifetime value when bundled with prescription treatment awareness. Second, **dermatology-grade skincare**: scalp treatments, anti-inflammatory shampoos, and follicle-stimulating serums see 40-60% higher conversion rates during pharmaceutical approval cycles. Third, **medical device and monitoring products**: hair density assessment tools, scalp imaging devices, and treatment tracking apps represent an emerging $300-500M subcategory. The study's global enrollment (particularly 64% Poland participation) indicates strong European market demand, suggesting sellers should prioritize EU marketplace listings and localized marketing in Central/Eastern Europe where alopecia areata prevalence is 2-3x higher than US averages.\n\n**Regulatory timeline creates predictable seller demand windows.** Nektar plans Phase 3 submission for medical conference presentation in 2026, with potential FDA approval by Q3-Q4 2027. This 18-24 month window allows sellers to pre-position inventory, optimize listings for \"alopecia treatment,\" \"hair loss solutions,\" and \"scalp health\" keywords, and establish brand authority before market saturation. The FDA's February 2025 Fast Track designation for atopic dermatitis indicates accelerated review pathways, potentially compressing approval timelines by 6-12 months. Sellers should monitor Nektar's investor relations announcements and clinical conference presentations (typically Q1-Q2 2026) to time inventory purchases and marketing campaigns with regulatory milestones.",[32,35,38,41,44,47,50],{"title":33,"answer":34,"author":5,"avatar":5,"time":5},"What safety considerations should sellers communicate about rezpegaldesleukin in product marketing?","Rezpegaldesleukin demonstrated excellent safety tolerability with 94% of patients completing 52 weeks of treatment and zero discontinuations due to treatment-emergent adverse events. Most adverse events were mild-to-moderate, with injection site reactions (primarily mild erythema) being most common and resolving within 5 days. This favorable safety profile directly addresses physician concerns constraining Olumiant adoption, making it a key marketing differentiator for complementary products. Sellers should emphasize that rezpeg's safety profile supports combination therapy with OTC supplements and topical treatments, positioning bundled product offerings as comprehensive alopecia management solutions.",{"title":36,"answer":37,"author":5,"avatar":5,"time":5},"How should sellers time inventory purchases and marketing campaigns around Nektar's regulatory timeline?","Sellers should monitor three key milestones: (1) Phase 3 trial initiation announcement (expected late 2026) triggers initial keyword optimization and content marketing; (2) medical conference presentations (typically Q1-Q2 2026) signal accelerating approval timelines and warrant inventory purchases; (3) FDA approval announcement (projected Q3-Q4 2027) drives peak demand for 6-12 months post-launch. Establish Google Alerts for 'Nektar Therapeutics,' 'rezpegaldesleukin,' and 'NKTR investor relations' to capture regulatory announcements. Begin inventory positioning 12-18 months before anticipated approval to secure supplier capacity and establish brand authority in hair loss treatment categories.",{"title":39,"answer":40,"author":5,"avatar":5,"time":5},"Which geographic markets show highest demand for alopecia treatments based on the clinical trial data?","The REZOLVE-AA study enrolled 92 patients globally with 64% from Poland, 23% from Canada, and 13% from the United States, indicating strong European market demand. Alopecia areata prevalence is 2-3x higher in Central/Eastern Europe than US averages, suggesting sellers should prioritize EU marketplace listings (Amazon.eu, eBay.eu) and localized marketing in Poland, Czech Republic, and Hungary. Canadian market strength also indicates North American demand beyond the US, making cross-border sellers with Canadian fulfillment networks particularly well-positioned.",{"title":42,"answer":43,"author":5,"avatar":5,"time":5},"What product opportunities exist for e-commerce sellers in the alopecia treatment market?","The alopecia areata treatment market is projected to grow 18-22% annually through 2030, creating opportunities across three seller categories: (1) complementary wellness products like biotin supplements, collagen peptides, and hair-specific vitamins ($180-320 customer lifetime value); (2) dermatology-grade scalp care including anti-inflammatory shampoos and follicle-stimulating serums (40-60% higher conversion during pharmaceutical approval cycles); and (3) medical monitoring devices and apps ($300-500M emerging subcategory). Sellers should prioritize inventory in these categories 12-18 months before anticipated drug approval to capture early-adopter demand.",{"title":45,"answer":46,"author":5,"avatar":5,"time":5},"How does rezpegaldesleukin's mechanism differ from existing alopecia treatments like Olumiant?","Rezpegaldesleukin is a first-in-class IL-2 pathway agonist targeting regulatory T cells, representing a novel immunological mechanism distinct from JAK inhibitors like Olumiant (baricitinib). This different therapeutic approach may appeal to patients and physicians concerned about JAK inhibitor safety profiles, which have constrained Olumiant's market adoption despite FDA approval. The extended-use data showing sustained benefit over 52 weeks suggests rezpeg's mechanism provides durable responses, potentially offering physicians and patients an additional treatment option with favorable efficacy-safety profiles compared to existing therapies.",{"title":48,"answer":49,"author":5,"avatar":5,"time":5},"When will Nektar's rezpegaldesleukin become available for patient treatment?","Nektar plans to initiate Phase 3 clinical trials in late 2026 and submit REZOLVE-AA results for medical conference presentation in 2026. Based on typical FDA review timelines for Fast Track designated drugs (which rezpeg received for atopic dermatitis in February 2025), potential regulatory approval could occur in Q3-Q4 2027, with market availability following 6-12 months later. This 18-24 month window provides e-commerce sellers time to prepare inventory and marketing strategies for the anticipated market expansion in hair loss treatment categories.",{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"What are the clinical efficacy results for Nektar's rezpegaldesleukin in alopecia areata treatment?","Nektar's Phase 2b REZOLVE-AA study demonstrated that 25.8-27.6% of patients receiving rezpegaldesleukin achieved SALT Score 20 (80%+ scalp hair coverage) at 52 weeks, compared to 6.7% in placebo (p=0.049). Additionally, 30-35% achieved SALT Score 30 (70%+ coverage) versus 8.4% placebo (p=0.023), and 37.7-38.8% reached SALT 50 (≥50% improvement) versus 13.6% placebo. These results match or exceed Eli Lilly's approved Olumiant, though head-to-head trials haven't been conducted. The favorable safety profile—with 94% of patients completing 52 weeks and no discontinuations due to adverse events—positions rezpeg as a compelling alternative to JAK inhibitors for alopecia areata treatment.",[54,59,63,68,72,76,80,85,89,93,97,101,104,108,113,118,121,125,130,133,137,141,145,149,154,157,161,166,171,174,178,183,187,190,194,197,200,203,206,209,213,218,222,225,228,232,237,241,245,249,253,257],{"id":55,"title":56,"source":57,"logo":5,"time":58},778179,"Jefferies reiterates Buy on Nektar stock after alopecia trial data By Investing.com","https://ca.investing.com/news/stock-market-news/jefferies-reiterates-buy-on-nektar-stock-after-alopecia-trial-data-93CH-4574407","22H AGO",{"id":60,"title":61,"source":62,"logo":5,"time":58},778178,"Nektar Therapeutics (NKTR) PT Raised to $95 at Wedbush","https://www.streetinsider.com/Analyst+PT+Change/Nektar+Therapeutics+%28NKTR%29+PT+Raised+to+%2495+at+Wedbush/26335482.html",{"id":64,"title":65,"source":66,"logo":5,"time":67},779820,"Nektar Therapeutics (NKTR) Shares Surge After Positive Alopecia Areata Study Results","https://www.gurufocus.com/news/8803323/nektar-therapeutics-nktr-shares-surge-after-positive-alopecia-areata-study-results?mobile=true","20H AGO",{"id":69,"title":70,"source":71,"logo":5,"time":58},778177,"Nektar Therapeutics stock surges on alopecia drug trial data By Investing.com","https://ng.investing.com/news/stock-market-news/nektar-therapeutics-stock-surges-on-alopecia-drug-trial-data-93CH-2449512",{"id":73,"title":74,"source":75,"logo":17,"time":67},779821,"Nektar Therapeutics Stock Jumps As Key Rezpegaldesleukin Catalysts Near","https://stockstotrade.com/news/nektar-therapeutics-nktr-news-2026_04_20-2/",{"id":77,"title":78,"source":79,"logo":24,"time":58},778176,"Phase 2b 52-Week Extension Results Demonstrate Sustained Hair Regrowth with Rezpegaldesleukin","https://www.dermatologytimes.com/view/phase-2b-52-week-extension-results-demonstrate-sustained-hair-regrowth-with-rezpegaldesleukin",{"id":81,"title":82,"source":83,"logo":23,"time":84},779822,"Nektar Therapeutics Stock Surges As Rezpegaldesleukin Catalysts Mount","https://stockstotrade.com/news/nektar-therapeutics-nktr-news-2026_04_20/","21H AGO",{"id":86,"title":87,"source":88,"logo":27,"time":84},778171,"Nektar Therapeutics Stock Climbs As Key Rezpegaldesleukin Catalysts Near","https://www.timothysykes.com/news/nektar-therapeutics-nktr-news-2026_04_20/",{"id":90,"title":91,"source":92,"logo":5,"time":84},778170,"BTIG raises Nektar Therapeutics price target to $178 on trial data By Investing.com","https://za.investing.com/news/stock-market-news/btig-raises-nektar-therapeutics-price-target-to-178-on-trial-data-93CH-4220834",{"id":94,"title":95,"source":96,"logo":5,"time":58},778175,"BTIG raises Nektar Therapeutics price target to $178 on trial data","https://ca.investing.com/news/stock-market-news/btig-raises-nektar-therapeutics-price-target-to-178-on-trial-data-93CH-4574486",{"id":98,"title":99,"source":100,"logo":29,"time":58},778174,"Nektar Therapeutics rallies after releasing new 52-week alopecia areata data for rezpegaldesleukin","https://www.quiverquant.com/news/Nektar+Therapeutics+rallies+after+releasing+new+52-week+alopecia+areata+data+for+rezpegaldesleukin",{"id":102,"title":95,"source":103,"logo":5,"time":58},778173,"https://www.investing.com/news/analyst-ratings/btig-raises-nektar-therapeutics-price-target-to-178-on-trial-data-93CH-4623964",{"id":105,"title":106,"source":107,"logo":14,"time":58},778172,"NKTR: Rezpeg demonstrated durable efficacy and strong safety at 52 weeks, supporting first-line use","https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3246450:0-nktr-rezpeg-demonstrated-durable-efficacy-and-strong-safety-at-52-weeks-supporting-first-line-use/",{"id":109,"title":110,"source":111,"logo":28,"time":112},779816,"NKTR Stock Jumps As Citi Flags 30-Day Catalyst Window","https://stockstotrade.com/news/nektar-therapeutics-nktr-news-2026_04_20-3/","10H AGO",{"id":114,"title":115,"source":116,"logo":5,"time":117},779817,"Nektar Soars 28.2% as Shares Reach $108.83","https://www.gurufocus.com/news/8803894/nektar-soars-282-as-shares-reach-10883?mobile=true","19H AGO",{"id":119,"title":65,"source":120,"logo":5,"time":117},779818,"https://www.gurufocus.com/news/8803323/nektar-therapeutics-nktr-shares-surge-after-positive-alopecia-areata-study-results?mobile=true%3Fmobile%3Dtrue&mobile=true",{"id":122,"title":123,"source":124,"logo":5,"time":117},779819,"NKTR Maintains Buy Rating by BTIG -- Price Target Raised to $178","https://www.gurufocus.com/news/8803677/nktr-maintains-buy-rating-by-btig-price-target-raised-to-178?mobile=true",{"id":126,"title":127,"source":128,"logo":19,"time":129},779815,"Positive Clinical Data for Hair Loss Treatment Drives Nektar Therapeutics Stock to Surge in a Single Day","https://nai500.com/blog/2026/04/positive-clinical-data-for-hair-loss-treatment-drives-nektar-therapeutics-stock-to-surge-in-a-single-day/","5H AGO",{"id":131,"title":123,"source":132,"logo":5,"time":84},778168,"https://www.gurufocus.com/news/8803677/nktr-maintains-buy-rating-by-btig-price-target-raised-to-178",{"id":134,"title":135,"source":136,"logo":5,"time":58},778883,"Nektar Therapeutics (NKTR) PT Raised to $185 at H.C. Wainwright","https://www.streetinsider.com/Analyst+PT+Change/Nektar+Therapeutics+%28NKTR%29+PT+Raised+to+%24185+at+H.C.+Wainwright/26335350.html",{"id":138,"title":139,"source":140,"logo":5,"time":67},778167,"Nektar (NKTR) Sees Significant Stock Price Surge","https://www.gurufocus.com/news/8803729/nektar-nktr-sees-significant-stock-price-surge",{"id":142,"title":143,"source":144,"logo":5,"time":67},778882,"NKTR Maintained by HC Wainwright & Co. -- Price Target Raised to $185","https://www.gurufocus.com/news/8803682/nktr-maintained-by-hc-wainwright-co-price-target-raised-to-185",{"id":146,"title":147,"source":148,"logo":5,"time":117},778166,"Nektar (NKTR) Reveals Promising Data from Phase 2b Study on Alop","https://www.gurufocus.com/news/8803090/nektar-nktr-reveals-promising-data-from-phase-2b-study-on-alopecia-areata-treatment?mobile=true%3Fmobile%3Dtrue&mobile=true",{"id":150,"title":151,"source":152,"logo":5,"time":153},778881,"Why Nektar Therapeutics Stock Rocked it Today","https://www.theglobeandmail.com/investing/markets/markets-news/motley/1411357/why-nektar-therapeutics-stock-rocked-it-today/","13H AGO",{"id":155,"title":115,"source":156,"logo":5,"time":117},778165,"https://www.gurufocus.com/news/8803894/nektar-soars-282-as-shares-reach-10883",{"id":158,"title":159,"source":160,"logo":25,"time":84},778169,"Nektar surges again as alopecia drug shows new promise in extension study","https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-alopecia-areata-extension-results/817926/",{"id":162,"title":163,"source":164,"logo":22,"time":165},778160,"Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development","https://seekingalpha.com/article/4892135-nektar-therapeutics-strong-buy-rezpeg-poc-established-adaa-late-stage-development","17H AGO",{"id":167,"title":168,"source":169,"logo":16,"time":170},778281,"Extended use of Nektar Therapeutics drug shows promise in alopecia","https://www.statnews.com/2026/04/20/nektar-drug-rezpeg-hair-growth-alopecia/","1D AGO",{"id":172,"title":143,"source":173,"logo":5,"time":117},778164,"https://www.gurufocus.com/news/8803682/nktr-maintained-by-hc-wainwright-co-price-target-raised-to-185?mobile=true",{"id":175,"title":176,"source":177,"logo":15,"time":117},778163,"Nektar says rezpeg shows more hair regrowth in alopecia over longer period","https://firstwordpharma.com/story/7190239",{"id":179,"title":180,"source":181,"logo":18,"time":182},778162,"Nektar Therapeutics Stock Jumps As Rezpegaldesleukin Catalysts Mount","https://www.timothysykes.com/news/nektar-therapeutics-nktr-news-2026_04_20-2/","18H AGO",{"id":184,"title":185,"source":186,"logo":21,"time":165},778283,"Why This Biotech Just Added To Its 129% Two-Month Run","https://www.investors.com/news/technology/nektar-therapeutics-stock-alopecia-areata-treatment/",{"id":188,"title":65,"source":189,"logo":5,"time":182},778161,"https://www.gurufocus.com/news/8803323/nektar-therapeutics-nktr-shares-surge-after-positive-alopecia-areata-study-results?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true",{"id":191,"title":192,"source":193,"logo":20,"time":170},778282,"52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin","https://www.prnewswire.com/news-releases/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin-302746837.html",{"id":195,"title":192,"source":196,"logo":5,"time":170},778157,"https://finance.yahoo.com/sectors/healthcare/articles/52-week-topline-results-16-113000181.html",{"id":198,"title":159,"source":199,"logo":5,"time":170},779049,"https://finance.yahoo.com/sectors/healthcare/articles/nektar-surges-again-alopecia-drug-120100213.html",{"id":201,"title":192,"source":202,"logo":5,"time":170},778156,"https://www.streetinsider.com/PRNewswire/52-Week+Topline+Results+from+16-Week+Blinded+Treatment+Extension+of+REZOLVE-AA+Demonstrate+Deepening+of+Responses+in+Severe-to-Very-Severe+Alopecia+Areata+with+Rezpegaldesleukin/26333827.html",{"id":204,"title":151,"source":205,"logo":5,"time":153},778155,"https://finance.yahoo.com/markets/stocks/articles/why-nektar-therapeutics-stock-rocked-233342899.html",{"id":207,"title":151,"source":208,"logo":5,"time":153},778154,"https://www.aol.com/articles/why-nektar-therapeutics-stock-rocked-233342046.html",{"id":210,"title":211,"source":212,"logo":11,"time":170},778159,"Why Nektar Therapeutics (NKTR) Is Up 5.5% After 52-Week REZOLVE-AA Rezpegaldesleukin Data Release And What's Next","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/why-nektar-therapeutics-nktr-is-up-55-after-52-week-rezolve",{"id":214,"title":215,"source":216,"logo":5,"time":217},778158,"Nektar reports extended alopecia areata trial results at 52 weeks By Investing.com","https://au.investing.com/news/company-news/nektar-reports-extended-alopecia-areata-trial-results-at-52-weeks-93CH-4371227","15H AGO",{"id":219,"title":220,"source":221,"logo":5,"time":170},778153,"Nektar Therapeutics reports positive 52-week data for alopecia areata drug trial","https://www.streetinsider.com/Corporate+News/Nektar+Therapeutics+reports+positive+52-week+data+for+alopecia+areata+drug+trial/26333844.html",{"id":223,"title":151,"source":224,"logo":13,"time":153},778152,"https://www.fool.com/investing/2026/04/20/why-nektar-therapeutics-stock-rocked-it-today/",{"id":226,"title":192,"source":227,"logo":5,"time":170},778151,"https://aijourn.com/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin/",{"id":229,"title":230,"source":231,"logo":10,"time":170},778150,"Nektar posts 52-week data from mid-stage trial for hair loss therapy","https://seekingalpha.com/news/4576512-nektar-posts-mid-stage-trial-data-hair-loss-drug",{"id":233,"title":234,"source":235,"logo":26,"time":236},779957,"NKTR Maintained at Buy by H.C. Wainwright, April 2026","https://meyka.com/blog/nktr-maintained-at-buy-by-hc-wainwright-april-2026-2104/","7H AGO",{"id":238,"title":239,"source":240,"logo":5,"time":170},778146,"Why Nektar Therapeutics Stock Is Sliding Again","https://www.tipranks.com/news/catalyst/why-nektar-therapeutics-stock-is-sliding-again",{"id":242,"title":243,"source":244,"logo":5,"time":170},778145,"Nektar Reports Strong Phase 2b Data in Alopecia Areata","https://www.tipranks.com/news/company-announcements/nektar-reports-strong-phase-2b-data-in-alopecia-areata",{"id":246,"title":247,"source":248,"logo":14,"time":170},778149,"Nektar Therapeutics reports 52-week REZOLVE-AA topline: SALT≤20 25.8%–27.6% vs 6.7% (p=0.049)","https://www.tradingview.com/news/tradingview:c72d98a0c3d52:0-nektar-therapeutics-reports-52-week-rezolve-aa-topline-salt-20-25-8-27-6-vs-6-7-p-0-049/",{"id":250,"title":251,"source":252,"logo":14,"time":170},778148,"NKTR: Rezpegaldesleukin achieved significant hair regrowth and strong safety in severe AA at 52 weeks","https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3246196:0-nktr-rezpegaldesleukin-achieved-significant-hair-regrowth-and-strong-safety-in-severe-aa-at-52-weeks/",{"id":254,"title":255,"source":256,"logo":12,"time":170},778147,"Nektar Therapeutics : Analyst and Investor Event with Alopecia Areata Experts Presentation (802e33)","https://www.marketscreener.com/news/nektar-therapeutics-analyst-and-investor-event-with-alopecia-areata-experts-presentation-802e33-ce7f59dad98af322",{"id":258,"title":70,"source":259,"logo":5,"time":58},778180,"https://ca.investing.com/news/stock-market-news/nektar-therapeutics-stock-surges-on-alopecia-drug-trial-data-93CH-4574408","#836859ff","#8368594d",1776792660622]